跳至主要内容
临床试验/JPRN-jRCT1031210377
JPRN-jRCT1031210377进行中(未招募)未知

Change in quality of life in the treatment change from 5-day treatment to patient-initiated therapy of anti-herpesvirus drugs in patients with recurrent herpes simplex -Exploratory prospective observational study- - Q-pid study

Hayakawa Jun0 个研究点目标入组 100 人开始时间: 2021年10月14日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • (1) Male or female Japanese subjects, >=20 years old at the time of signing informed consent
  • (2) Subjects who may recur herpes simplex three times or more per year
  • (3) Subjects who can recognize the early symptoms of recurrent herpes simplex (a feeling of strangeness, burning or itching, etc)
  • (4) Subjects who had the early symptoms of herpes simplex or skin rashes for 72 hours or longer
  • (5) Subjects who received the oral anti-herpesvirus agents for 5 days and wish to receive the PIT (patient-initiated therapy) at the next recurrence of herpes simplex

排除标准

  • (1)Any known history of hypersensitivity to the excipient (famciclovir) of the research drug
  • (2)Subjects whose immune response may decrease due to hematopoietic stem cell transplantation, organ transplantation or HIV (human immunodeficiency virus) infection
  • (3) A person who has participated in a clinical study of a vaccine for herpes simplex or herpes zoster.
  • (4) Persons who have participated in clinical research, clinical trials, or post-marketing clinical trials of therapeutic agents for herpes simplex or herpes zoster during the 6 months prior to the date of consent.
  • (5) Those who are participating or have participated in other clinical research, clinical trials or post-marketing clinical trials other than (3) or (4) within 4 months prior to the date of consent.
  • (6)Pregnant women, women of child-bearing potential, or lactating women
  • (7)Subjects or his/her partner who will not use adequate contraceptive methods between the time of signing informed consent and the completion of the research
  • (8)Subjects who have received suppressive treatment for herpes simplex within 6 months before signing informed consent
  • (9)Subjects who are ineligible to participate in this research by the consideration of the principal researcher or sub-researcher

研究者

发起方
Hayakawa Jun

相似试验